BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Zenotech Laboratories Ltd. Share Price

NSE
BSE

BSE : 532039

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

High

Price Summary

Previous Close ₹44.20
Day's Range ₹44.11 - ₹45.50
Open ₹45.50
52 Week Range ₹33.55 - ₹67.00
Volume 1,130
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 0.50
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 0.00
TTM EPS (₹) -2.05
P/E Ratio 0.00
Book Value(₹) 0.00
PAT Margin (%) -181.10
Face Value (₹) 10.00
ROCE(%) -9.32

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 121.31 430.47
Expenses N/A N/A
PBT 31.86 106.92
Operating profit 0.0 0.0
Net profit 12.3 56.13

Shareholding Pattern

Promoters (% Holding)

68.84%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

30.17%

FI/Banks/Insurance (% Holding)

0.01%

Government (% Holding)

0.98%

FII

0.00%

About Zenotech Laboratories Ltd.

Founded 1989

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,26,937.66 1,789.90 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,79,361.19 6,707.35 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,51,384.95 4,492.70 3,140.10 - 3,140.10
Apollo Hospitals Enterprise Ltd. 1,22,585.05 8,515.70 6,696.50 - 6,696.50
Zydus Lifesciences Ltd. 1,11,264.32 1,104.05 835.50 - 835.50
Cipla Ltd. 1,11,220.10 1,380.10 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,05,898.64 1,270.30 1,148.40 - 1,148.40
Lupin Ltd. 1,03,490.01 2,262.10 1,836.80 - 1,836.80
Mankind Pharma Ltd. 98,745.27 2,399.05 1,909.70 - 1,909.70
Max Healthcare Institute Ltd. 97,640.68 1,017.20 903.00 - 903.00
no-content No Records Found

Latest News

Apr
30
2026
EQUITY Posted on Apr 30th 2026

Zenotech Laboratories informs about newspaper publication

Pursuant to the provisions of Regulation 47 of the Listing Regulations, Zenotech Laboratories has enclosed copies of advertisement published today, i.e., April 30, 2026, for the extract of Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026, in Business Standard (English Newspaper) all Editions and Telugu Prabha (Telugu Newspaper) Hyderabad Edition.
The above information is a part of company’s filings submitted to BSE.
Read More
Apr
29
2026
EQUITY Posted on Apr 29th 2026

Zenotech Laboratories informs about outcome of board meeting

Further to its communication dated April 23, 2026, Zenotech Laboratories has informed that the Meeting of the Board of Directors of the Company was held today, April 29, 2026, which commenced at 11:30 am and concluded at 3:50 pm IST. The Board has, approved the Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026, pursuant to Regulation 33 of SEBI (Listing and Disclosure Requirements) Regulations, 2015 (Listing Regulations), along with the Auditor’s Report thereon and Declaration under Regulation 33(3)(d) of Listing Regulations are annexed.

The above information is a part of company’s filings submitted to BSE.

Read More
Apr
23
2026
EQUITY Posted on Apr 23rd 2026

Zenotech Laboratories inform about board meeting

Zenotech Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, April 29, 2026, to consider and approve Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026. Further to its communication dated March 26, 2026, the Trading Window has been closed from April 01, 2026 and will remain closed until May 01, 2026, after 48 hours of the declaration of financial results.

The above information is a part of company’s filings submitted to BSE.

Read More
Jun
10
2026
EQUITY Posted on Jun 10th 2026

Beryl Drugs informs about disclosure

Beryl Drugs has informed that the exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi.
The above information is a part of company’s filings submitted to BSE. 
Read More
Jun
10
2026
EQUITY Posted on Jun 10th 2026

Concord Biotech informs about updates

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Concord Biotech has informed that the Company has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg. Tofacitinib tablets are indicated for the treatment of adult patients with Moderately to severely active rheumatoid arthritis (RA), Active psoriatic arthritis (PsA), Active ankylosing spondylitis (AS), Moderately to severely active ulcerative colitis (UC), Active PsA, Active polyarticular course juvenile idiopathic arthritis (pcJIA). According to market estimates, the U.S. market for Tofacitinib Tablets both strengths put together is approximately US$ 500 million. The approval positions the Company to capitalize on these attractive market opportunities, enhance its product offerings, and support its long-term growth strategy across the U.S. and international markets. The requisite details of terms of the provisions of Regulation 30 read with Schedule III and SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30, 2026 are enclosed.
The above information is a part of company’s filings submitted to BSE. 
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Zenotech Laboratories Ltd. ?

The current share price of Zenotech Laboratories Ltd. is ₹44.20 as of 2026-06-10.

The market capitalisation of Zenotech Laboratories Ltd. is ₹272.38 as of 2026-06-09.

The 1-year return of Zenotech Laboratories Ltd. is -18.67% as of 2025-06-09.

The P/E ratio of Zenotech Laboratories Ltd. is 56.45 as of 2026-06-10.

The 52-week high and low of Zenotech Laboratories Ltd. are ₹67.00 and ₹33.55, respectively, as of 2026-06-10.

The dividend yield of Zenotech Laboratories Ltd. is 0.0% as of2026-06-09.

You can buy Zenotech Laboratories Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Zenotech Laboratories Ltd. is .

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore